Drug in Drug : A Host-Guest Formulation of Azocalixarene with Hydroxychloroquine for Synergistic Anti-Inflammation

© 2022 Wiley-VCH GmbH.

Bibliographische Detailangaben
Veröffentlicht in:Advanced materials (Deerfield Beach, Fla.). - 1998. - 34(2022), 32 vom: 01. Aug., Seite e2203765
1. Verfasser: Li, Shihui (VerfasserIn)
Weitere Verfasser: Ma, Rong, Hu, Xin-Yue, Li, Hua-Bin, Geng, Wen-Chao, Kong, Xianglei, Zhang, Chao, Guo, Dong-Sheng
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2022
Zugriff auf das übergeordnete Werk:Advanced materials (Deerfield Beach, Fla.)
Schlagworte:Journal Article anti-inflammation biomedical materials combinational therapy macrocycles supramolecular chemistry Anti-Inflammatory Agents Pharmaceutical Preparations Hydroxychloroquine 4QWG6N8QKH
LEADER 01000naa a22002652 4500
001 NLM342023489
003 DE-627
005 20231226013127.0
007 cr uuu---uuuuu
008 231226s2022 xx |||||o 00| ||eng c
024 7 |a 10.1002/adma.202203765  |2 doi 
028 5 2 |a pubmed24n1140.xml 
035 |a (DE-627)NLM342023489 
035 |a (NLM)35680644 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Li, Shihui  |e verfasserin  |4 aut 
245 1 0 |a Drug in Drug  |b A Host-Guest Formulation of Azocalixarene with Hydroxychloroquine for Synergistic Anti-Inflammation 
264 1 |c 2022 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 11.08.2022 
500 |a Date Revised 11.08.2022 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a © 2022 Wiley-VCH GmbH. 
520 |a Macrocyclic delivery and therapeutics are two significant topics in supramolecular biomedicine. The functional integration of these topics would open new avenues for treating diseases synergistically. However, these two individual topics have only been occasionally merged, probably because of the lack of functionalized design of macrocyclic host and the lack of efficient recognition between host and guest drugs. Herein, a "drug-in-drug" strategy is proposed, in which an active drug is encapsulated by a macrocycle possessing therapeutic activity to form a multifunctional supramolecular active pharmaceutical ingredient. As a proof-of-concept, a complex of hydroxychloroquine (HCQ) with sulfonated azocalix[4]arene (HCQSAC4A) is prepared to treat rheumatoid arthritis (RA) in a combined fashion. SAC4A is a therapeutic agent that exhibits scavenging capacity for reactive oxygen species and exerts an anti-inflammatory effect. It is also a hypoxia-responsive carrier that can deliver HCQ directly to the inflammatory articular cavity. Consequently, HCQ@SAC4A achieves the synergistic anti-inflammatory effect on both inflamed RAW 264.7 cells and RA rats. This effect is attributed to the temporal and spatial consistency of the two active ingredients of the complex. As a new paradigm for combinational therapy, the drug-in-drug strategy advances in easy preparation, mix-and-match combination, and precise ratiometric control 
650 4 |a Journal Article 
650 4 |a anti-inflammation 
650 4 |a biomedical materials 
650 4 |a combinational therapy 
650 4 |a macrocycles 
650 4 |a supramolecular chemistry 
650 7 |a Anti-Inflammatory Agents  |2 NLM 
650 7 |a Pharmaceutical Preparations  |2 NLM 
650 7 |a Hydroxychloroquine  |2 NLM 
650 7 |a 4QWG6N8QKH  |2 NLM 
700 1 |a Ma, Rong  |e verfasserin  |4 aut 
700 1 |a Hu, Xin-Yue  |e verfasserin  |4 aut 
700 1 |a Li, Hua-Bin  |e verfasserin  |4 aut 
700 1 |a Geng, Wen-Chao  |e verfasserin  |4 aut 
700 1 |a Kong, Xianglei  |e verfasserin  |4 aut 
700 1 |a Zhang, Chao  |e verfasserin  |4 aut 
700 1 |a Guo, Dong-Sheng  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Advanced materials (Deerfield Beach, Fla.)  |d 1998  |g 34(2022), 32 vom: 01. Aug., Seite e2203765  |w (DE-627)NLM098206397  |x 1521-4095  |7 nnns 
773 1 8 |g volume:34  |g year:2022  |g number:32  |g day:01  |g month:08  |g pages:e2203765 
856 4 0 |u http://dx.doi.org/10.1002/adma.202203765  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 34  |j 2022  |e 32  |b 01  |c 08  |h e2203765